<DOC>
	<DOCNO>NCT00991224</DOCNO>
	<brief_summary>This research study carry study new way possibly treat HIV . T‐cells one white blood cell use body fight HIV . CD8 T‐cells type T‐cell use body detect kill cell infect foreign virus organism , include HIV virus . CD8 T‐cells must identify HIV virus order kill . Because HIV constantly change way look CD8 T‐cells , HIV virus escape detection kill CD8 T‐cells . This research study use T cell receptor ( TCR ) protein specific HIV ( SL9 TCR ) add CD8 T‐cells laboratory order help CD8 T‐cells recognize constantly change HIV virus make able fight HIV efficiently . TCR stand T cell receptor . TCRs find surface T cell allow T cell recognize cell . Laboratory study show CD8 T‐cells modify SL9 TCRs , kill cell infect HIV well normal CD8 T‐cells . On basis laboratory result , potential SL9 TCRs may work people infected HIV improve immune system kill HIV infected cell thus may help control HIV infection . Two different SL9 TCRs test study , WT‐gag‐TCR α/6‐gag‐TCR . Two different type SL9 TCRs use research study laboratory study suggest different SL9 TCRs function differently depend amount virus body . A goal clinical study test effect infusion either SL9 TCR presence absence viral load . All subject receive WT‐gag‐TCR α/6‐gag‐TCR T cell enrol Long Term Follow study monitor subject . Subjects follow every 6 month five year follow 1st infusion T cell . If WT‐gag‐TCR α/6‐gag‐TCR T cell longer find blood five year , subject contact yearly next 10 year . If WT‐gag‐TCR α/6‐gag‐TCR T cell find blood five year 1st infusion T cell , subject continue see year WT‐gag‐TCR α/6‐gag‐TCR T cell longer find blood maximum 15 year .</brief_summary>
	<brief_title>Redirected High Affinity Gag‐Specific Autologous T Cells HIV Gene Therapy</brief_title>
	<detailed_description>See Above</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Age 18 year old Karnofsky Performance 80 high HLAA2 Positive Chronic HIV1 infection On stable HAART regimen ( change within 4 week study entry ) Willing undergo limit treatment interruption antiretroviral medication CD4+ T cell count ≥450 cells/mm3 Documented CD4 nadir ≥200 cells/mm3 Undetectable HIV1 RNA ARMS 1 2 , least singe document historic viral load set point read Lab Values : Hgb≥10 male ; ≥9.5 females ; ANC≥1000/mm3 ; Platelets≥1000,000/mm3 ; Creatinine≤1.5 mg/dL ; AST , ALT ≤ 2.5xULN Current prior AIDS diagnosis Previous participation gene therapy use integrate vector ( subject treat Placebo exclude ) History cancer malignancy ( allow successfully treat basal cell squamous cell carcinoma skin ) Have history current exam indicative active unstable cardiac disease hemodynamic instability Have history current exam indicative bleeding diathesis Previous treatment HIV experimental vaccine within 6 month prior screen Use chronic corticosteroid , hydroxyurea immunomodulating agent IL2 , interferon alpha , interferon gamma , granulocyte colony stimulate factor within 30 day prior study entry ( inhaled steroid exclusionary ) Currently breast feeding , pregnant unwilling use acceptable method birth control Use aspirin , dipyridamole , warfarin medication likely affect platelet function aspect blood coagulation 2 week period prior leukapheresis Active drug alcohol use/dependence Serious illness require systemic treatment and/or hospitalization within 30 day prior study entry Receipt vaccination within 30 day prior study entry Have know allergy hypersensitivity human serum albumin , DMSO Dextran 40</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV therapeutic vaccine</keyword>
</DOC>